首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷超音波

市場調查報告書

商品編碼

1374787

全球心血管超音波系統市場-2023-2030

Global Cardiovascular Ultrasound System Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

心血管超音波系統也稱為超音波心動圖系統，是一種醫學影像設備，用於對體內心臟和血管進行非侵入性評估和可視化。它利用高頻聲波（超音波）創建心臟結構、功能和血流模式的即時影像和視訊。這項技術對於診斷和監測各種心血管疾病至關重要，例如心臟瓣膜疾病、先天性心臟缺陷、心肌疾病、血管異常等。

心臟超音波檢查應使用低頻探頭進行，該探頭佔地面積小，可安裝在肋骨之間，並使用心臟設定。超音波的定義是頻率大於 20,000 赫茲 (Hz)。超音波探頭透過身體發送聲波，患者聽不到或感覺不到。當聲波從內部結構反彈時，該技術解釋返回波的「迴聲」並即時重建患者心臟的動態影像。

市場動態：促進因素

對先進心血管超音波系統的需求不斷增加

對先進心血管超音波系統的需求不斷成長預計將在預測期內推動市場發展。先進的系統包括人工智慧功能，可透過執行微創手術來改善患者的治療效果。這些先進的系統有助於臨床醫生獲得更快、更可重複的測試。

例如，2023 年 8 月 25 日，西門子 Healthineers 推出了 Acuson Origin，這是一款專用心血管超音波系統，具有全新、強大的人工智慧 (AI) 功能。 Acuson Origin 旨在改善患者治療效果並幫助醫生更有效地進行微創心臟手術，解決心血管患者護理的整個連續過程，包括診斷、結構性心臟、電生理和兒科手術。

此外，2020 年10 月12 日，GE Healthcare 為其Vivid 心血管超音波系統Ultra Edition 套裝發布了美國FDA 510k 許可，其中包括基於人工智慧(AI) 的新功能，使臨床醫生能夠持續獲得更快、更可重複的檢查。

此外，超音波技術的不斷進步導致了更先進、更複雜的心血管超音波系統的發展。這些系統提供更高的影像品質、更高的診斷準確性以及增強的功能，例如 3D 和 4D 成像、應變成像和對比度增強成像。這些創新使有效診斷和治療心血管疾病變得更加容易。

例如，2023 年 1 月 22 日，飛利浦在全球推出了下一代緊湊型心血管攜帶式超音波解決方案 Compact 5000 系列。這種新型超音波設備具有攜帶性和多功能性，且不會影響影像品質或性能，旨在為更多患者帶來與優質推車超音波系統相關的診斷品質。

此外，先進的設備有助於提供增強的影像品質和便利性。例如，2021 年9 月30 日，全球醫療設備公司、三星電子子公司Samsung Medison 推出了V8，這是一款新型高級心臟病超音波系統，可為所有醫療專業人員提供增強的影像品質、可用性和便利性。

此外，心血管疾病盛行率的增加、FDA 批准的增加、對非侵入性診斷方法的需求不斷增加、新系統開發中意識的提高和技術進步是預計在預測期內推動市場的因素。

限制

與機器相關的併發症、心血管超音波系統的高成本以及缺乏訓練有素的專業人員等因素預計將阻礙市場的發展。

A cardiovascular ultrasound system also known as an echocardiography system is a medical imaging device used for non-invasive assessment and visualization of the heart and blood vessels within the body. It employs high-frequency sound waves (ultrasound) to create real-time images and videos of the heart's structure, function, and blood flow patterns. This technology is essential for diagnosing and monitoring various cardiovascular conditions, such as heart valve diseases, congenital heart defects, heart muscle disorders, vascular abnormalities and others.

Cardiac ultrasound should be performed with a low-frequency probe that has a small footprint that can fit between the ribs, using a cardiac setting. Ultrasound is defined as a frequency greater than 20,000 Hertz (Hz). The ultrasound probe sends sound waves, which the patient does not hear or feel, through the body. When the sound waves bounce off internal structures, the technology interprets the "echos" of the returning waves and reconstructs a moving picture of the patient's heart in real-time.

Market Dynamics: Drivers

Increasing demand for advanced cardiovascular ultrasound systems

The increasing demand for advanced cardiovascular ultrasound systems is expected to drive the market over the forecast period. The advanced systems include artificial intelligence features that are responsible for better patient outcomes by performing minimally invasive procedures. These advanced systems helps to enable clinicians to acquire faster and more repeatable tests.

For instance, on August 25, 2023, Siemens Healthineers launched the Acuson Origin, a dedicated cardiovascular ultrasound system with new, robust artificial intelligence (AI) features. Designed to improve patient outcomes and help physicians perform minimally invasive cardiac procedures more efficiently, the Acuson Origin addresses the entire continuum of cardiovascular patient care, including diagnostic, structural heart, electrophysiological, and pediatric procedures.

Additionally, on October 12, 2020, GE Healthcare released U.S. FDA 510k clearance for its Ultra Edition package on Vivid cardiovascular ultrasound systems, which includes new features based on artificial intelligence (AI) that enable clinicians to acquire faster, more repeatable exams consistently.

Moreover, ongoing advancements in ultrasound technology have led to the development of more advanced and sophisticated cardiovascular ultrasound systems. These systems offer higher image quality, improved diagnostic accuracy, and enhanced features such as 3D and 4D imaging, strain imaging, and contrast-enhanced imaging. These innovations make it easier to diagnose and treat cardiovascular conditions effectively.

For instance, on January 22, 2023, Philips launched globally their next-generation compact cardiovascular portable ultrasound solution, the Compact 5000 Series. This new ultrasound is designed for portability and versatility without compromising image quality or performance and aims to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients.

In addition, the advanced devices helps to provide enhanced image quality and convenience. For instance, on September 30, 2021, Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, introduced the V8, a new premium cardiology ultrasound system that provides enhanced image quality, usability, and convenience for all medical professionals.

Further, the increasing prevalence of cardiovascular conditions, rising FDA approvals, rising demand for non-invasive diagnostic methods, increasing awareness and technological advancements in the development of novel systems are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the machines, the high cost of the cardiovascular ultrasound systems and lack of trained professionals are expected to hamper the market.

Segment Analysis

The global cardiovascular ultrasound system market is segmented based on type, technology, portability, end-user and region.

The transesophageal echocardiogram segment accounted for approximately 46.2% of the cardiovascular ultrasound system market share

The transesophageal echocardiogram segment is expected to hold the largest market share over the forecast period. A transesophageal echocardiogram is valuable for diagnosing conditions that may not be adequately visualized with other tests, and it is often used in cases of suspected infective endocarditis, aortic dissection, or complex valve pathology. The transesophageal echocardiography system is mainly used to manage and guide care for many cardiovascular patients.

For instance, on June 30, 2022, Clarius Mobile Health and ImaCor Inc. announced a partnership and launched a handheld transesophageal echocardiography (TEE) system designed to manage and guide care for the most critically ill patients in the Intensive Care Unit (ICU).

Moreover, a transesophageal echocardiogram shows a detailed view of the heart's structure and function. It can help diagnose and manage many different cardiovascular conditions. The transesophageal echocardiogram uses transesophageal echocardiography for the diagnosis and management of many diseases.

In May 2022, Philips announced the international launch of EchoNavigator 4.0, EPIQ CVXi interventional cardiology ultrasound system. By integrating real-time transoesophageal echocardiography (TEE), which places the ultrasound transducer close to the heart, and X-ray fluoroscopy, EchoNavigator 4.0 helps interventional teams to decide, guide, treat, and confirm complex structural heart disease therapy, such as heart valve repair or replacement.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and technological advancements. North America especially the United States is very well known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in research activities, leads to the launch of advanced cardiovascular ultrasound systems with better features.

For instance, on August 25, 2023, GE HealthCare launched the Vscan Air SL, a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions. The latest addition to the Vscan product suite, Vscan Air SL features GE HealthCare's proprietary SignalMax and Xdclear technology that provide high levels of penetration, resolution, and sensitivity in imaging performance with an industry-leading single crystal transducer technology.

Furthermore, the technological advancements in the region is also a considerable factor in the region. North America is home to several universities and research institutions that collaborate with the healthcare industry. These collaborations lead to the development of technologically innovative cardiovascular ultrasound systems, which increases the knowledge about their benefits, leading to market dominance in the region.

Competitive Landscape

The major global players in the cardiovascular ultrasound system market include: Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare, Hitachi, Ltd., CANON MEDICAL SYSTEMS CORPORATION, ESAOTE SPA, SAMSUNG HEALTHCARE, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., FUJIFILM Holdings Corporation, Whale Imaging Inc. and among others.

Key Developments

On June 23, 2023, UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial intelligence, released the announcement about the partnership with point-of-care ultrasound innovator EchoNous, to enable more healthcare professionals to perform cardiac ultrasound and help increase patient access to cardiac care. The new collaboration was announced at ASE 2023, the premier event for bringing together echo professionals.
On January 27, 2023, FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger Fujifilm Healthcare portfolio, launched the new Sonosite PX ultrasound system. Sonosite PX is the next generation in Sonosite POCUS, with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor.
In April 2022, FUJIFILM Sonosite, Inc. launched a new T8-3 transesophageal transducer and Cardiac Resuscitation exam type, to assist clinicians in using transesophageal ultrasound (TEU) at the point of care.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global cardiovascular ultrasound system market. During the early stages of the pandemic, many healthcare facilities postponed or canceled elective medical procedures, including non-urgent cardiac imaging tests such as cardiovascular ultrasounds. This led to a temporary decline in the demand for cardiovascular ultrasound systems. The pandemic also disrupted the supply chain of these devices globally.

Why Purchase the Report?

To visualize the global cardiovascular ultrasound system market segmentation based on type, technology, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of cardiovascular ultrasound system market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global cardiovascular ultrasound system market report would provide approximately 69 tables, 71 figures, and 188 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Technology
3.3. Snippet by Portability
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Demand for Advanced Cardiovascular Ultrasound Systems
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of the Equipment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Stress Echocardiogram*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Transesophageal Echocardiogram
7.4. Transthoracic Echocardiogram
7.5. Contrast Echocardiogram
7.6. Doppler Echocardiogram
7.7. Others

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. 2D Ultrasound*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. 3D Ultrasound
8.4. 4D Ultrasound
8.5. Others

9. By Portability

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 9.1.2. Market Attractiveness Index, By Portability
9.2. Portable*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Handheld

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Cardiovascular Diagnostic Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. UK
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Siemens Healthineers AG*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Koninklijke Philips N.V.
13.3. GE HealthCare
13.4. Hitachi, Ltd.
13.5. CANON MEDICAL SYSTEMS CORPORATION
13.6. ESAOTE SPA
13.7. SAMSUNG HEALTHCARE
13.8. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
13.9. FUJIFILM Holdings Corporation
13.10. Whale Imaging Inc.

LIST NOT EXHAUSTIVE